CAR-T-cell therapy has ... Her expertise spans from assay development to validation of cell-based assays. She has previously validated flow cytometry-based T-cell memory assays for a hepatitis ...

The Agilent xCELLigence RTCA eSight simply requires target cancer cell seeding and a subsequent addition of CAR T cells to provide a direct assessment of target cell number, cell size, and cell ...

Excitingly, these finding support that “this assay can be used in ongoing translational research studies to investigate CAR-T cell and TCR-T cell trafficking,” commented the authors. “Insight into ...

Chimeric antigen receptor (CAR) T cell ... Cell viabilities were monitored daily using acridine orange / propidium iodide (AO/PI) stain and its respective dual fluorescent assay.

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed ... real-time quantitative polymerase-chain-reaction (qPCR) assays. Experimental details regarding other correlative studies ...

Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

and efficient alternative to cell line target cells. This helps CAR-T developers accelerate assay validation and lot release, while avoiding the operational burden, variability and chain-of ...

CAR T-cell therapy has significantly improved outcomes for B-ALL patients, but relapse still occurs in over 50% of cases, leaving many with limited treatment options. Ongoing research aims to ...

Similarly, in an assay of chronic antigen exposure, both CAR T and TCR T cells with RASA2 ablated by CRSPR-Cas9 appeared more active and maintained effective cancer killing, whereas control-edited ...

Update: As of November 29, 2023, the FDA has received a total of 20 reports of T cell malignancy including T cell lymphomas and leukemias in patients who received CAR-T therapy. The announcement ...